EU Nations Join Forces Against Gilead Sciences, Inc. (GILD)'s "Exorbitant" Hepatitis C Drug
7/11/2014 7:16:01 AM
Paris (AFP) - France said Thursday it has joined forces with 13 other European countries to negotiate a lower price for a promising new hepatitis C drug that has drawn controversy for its astronomical cost.
Sovaldi, made by US pharmaceutical firm Gilead Sciences, has shown huge potential at helping cure the liver disease but its price -- more than 50,000 euros ($68,000) for a 12-week course of treatment -- has health authorities concerned.
Help employers find you! Check out all the jobs and post your resume.
comments powered by